OncLive SOSS

Authors

Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

Latest:

Updates in the Management of Hairy Cell Leukemia

Farhad Ravandi, MBBS

Latest:

Dr. Ravandi on BiTE Antibody AMG 330 Data in Relapsed/Refractory AML

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.

Farhad Ravandi, MD

Latest:

Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Farrukh Awan, MBBS

Latest:

Dr Awan on Treatment Considerations With Pirtobrutinib in Hematologic Malignancies

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Farrukh Awan, MD

Farrukh Awan, MD, is a professor in the Department of Internal Medicine and member of the Division of Hematology and Oncology at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center.

Latest:

Dr Awan on Patient Characteristics Associated With CAR T-Cell Candidacy in CLL

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Farrukh Awan, MD, University of Texas Southwestern Medical Center

Farshid Dayyani, MD, University of California Irvine School of Medicine

Farzana Sayani, MD, University of Pennsylvania

Fatima Cardoso, MD

Latest:

Dr Cardoso on Outcomes With Elinzanetant for Hot Flashes in HR+ Breast Cancer

Fatima Cardoso, MD, MSc, FESMO, discusses quality-of-life outcomes with elinzanetant for the management of hot flashes in hormone receptor–positive breast cancer.

Fausto Roila, MD

Latest:

Dr. Roila on Aprepitant for the Prevention of Cisplatin-Induced Delayed Emesis

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

Federico Aucejo, MD

Latest:

First Liver Transplant Surgery Performed in Patient With CRC Metastases

Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.

Federico Ustaris, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Felix M. Chinea, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Ferdinandos Skoulidis, MD, PhD, MRCP

Latest:

Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

Filip Janku, MD, PhD

Latest:

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Filipa Lynce, MD

Latest:

Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast Cancer

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Filippo Pietrantonio, MD

Filippo Pietrantonio, MD, is a medical oncologist and head of the Gastrointestinal Oncology Unit at Fondazione IRCCS Istituto Nazionale dei Tumori.

Latest:

Dr Pietrantonio on Future Directions of Evaluating Amivantamab in CRC

Filippo Pietrantonio, MD, highlights the future directions of assessing amivantamab with or without chemotherapy in patients with colorectal cancer.

Fiona McCaughan, RN, MS

Latest:

Facilitating Intraperitoneal Chemotherapy Completion

Fiona McCaughan on Nurses Facilitating Intraperitoneal Chemotherapy Completion

Floor J. Backes, M

Latest:

Dr. Backes on Pelvic Exenteration Surgery in Gynecologic Cancer

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Floortje J. Backes, MD

Floortje J Backes, MD, is a gynecologic oncologist and a professor in the College of Medicine at The Ohio State University Wexner Medical Center and the OSUCCC – James.

Latest:

Ongoing Research to Watch in Ovarian Cancer

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.